ARCHIVES

Vaccine Increases PFS 146%, OS 60% In Phase II Clinical Trial

This article is from The Cancer Letter archive.

Vol. 36 No. 5 | May 31, 2013

Download PDF Visit The Full Archive

Related Articles

FDA To Once Again Review ESA Label To Reflect Results Of Negative Studies.

December 7, 2007

Reexamine Mandates, Samuels Suggests

February 17, 1984

DRCCA Board Oks Noncompetitive Contract Concepts

November 11, 1983

Cancer Control Planning Conference Delayed To 1977

August 13, 1976

Troubles of Two Landmark Cancer Drugs, Celebrex and Iressa, Likely to Shape cancer Prevention, FDA Policy. FDA Mulls Withdrawal of Iressa.

January 7, 2005

Upton May Leave NCI Soon, Newell Accepts Post At M.D. Anderson to Head Cancer Prevention

August 17, 1979